CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 92 enrolled
Drug / intervention
Clarithromycin +1 moredrug
Likely dose
Clarithromycin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01298336
NCT01298336Phase 3Completed
CompareCT.gov

Efficacy of Clarithromycin or Moxifloxacin Containing Regimen in 6 Months Sputum Conversion of Mycobacterium Xenopi

Centre Hospitalier Universitaire, Amiens·interventional·Posted Feb 17, 2011·Updated Nov 19, 2025

In Brief

A Phase 3 clinical trial evaluating Clarithromycin and Moxifloxacin for Atypical; Mycobacterium, Pulmonary, Tuberculous. Completed, enrolled 92 participants across 52 sites.

Detailed Summary

The purpose of this study is to determine the 6-months sputum conversion rate with a clarithromycin or moxifloxacin containing regimen in patients with a M. xenopi pulmonary infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtypical; Mycobacterium, Pulmonary, Tuberculous
CountriesFrance
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 17, 2011
Enrollment StartMar 2, 2011
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 15.4 years ago

Interventions

Clarithromycindrug

500 mg twice a day seven days a week

Moxifloxacindrug

400 mg per day seven days a week